menu
    • menu

    Company profile for Hikma Pharmaceuticals

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Founded more than 40 years ago, our purpose has always been to provide high-quality, affordable medicines to the people who need them. Based on the solid foundation we have built, we will continue to innovate and find practical solutions to transform the lives of the millions of people we serve. We were founded in Jordan in 1978, where we established ourselves as a leading supplier of branded generics and in-licensed products....
    Founded more than 40 years ago, our purpose has always been to provide high-quality, affordable medicines to the people who need them. Based on the solid foundation we have built, we will continue to innovate and find practical solutions to transform the lives of the millions of people we serve. We were founded in Jordan in 1978, where we established ourselves as a leading supplier of branded generics and in-licensed products. We built our presence in the MENA and established the first FDA-inspected manufacturing plant in the region. It was also in this decade that we extended our reach beyond the Middle East and acquired land in Portugal.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Hikma Pharmaceuticalsunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    1 New Burlington Place, Mayfair, London, W1S 2HR
    Telephone
    Telephone
    +44 (0) 20 7399 2760
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.hikma.com/home/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/hikma-pharmaceuticals/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/hikmapharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    “Translational Pharmaceutics, our flagship platform for drug development, empowers our clients with unparalleled flexibility”

    “Translational Pharmaceutics, our flagship platform for drug development, empowers our clients with unparalleled flexibility”

    This week, SpeakPharma interviews Denise Sutton, Chief Operating Officer and Site Head at Quotient Sciences’ Nottingham facility in the UK. Quotient Sciences is a drug development and manufacturing accelerator that offers the innovative Translational Pharmaceutics platform to support customers in overcoming drug development challenges. Sutton has been with the company for over 25 years. In this interview, she provides insights into the evolution of Quotient Sciences’ Nottingham facility and discusses how the organization has transformed from a small 10-bed clinic to a comprehensive drug development campus with six GMP suites. She also shares her perspective on the company’s unique approach to integrating drug development services. HIGHLIGHTS// evolution of Quotient Sciences’ Nottingham facility/ unique approach to integrating drug development services How has the Nottingham site transformed from when it was founded, to what it is today? Initially, we were a small company with fewer than 50 employees, a 10-bed clinic, and a single lab. Over 90 percent of our work focused on gamma scintigraphic imaging (a diagnostic test that creates images of the body’s internal organs and tissues using gamma rays). Due to the short half-life radionuclides we used to label dosage forms, every product we manufactured had a limited time to be dosed. At the end of 1999, we moved our headquarters to a purpose-built, two-storey facility—now known as Trent House on our now much larger Nottingham campus. We built three good manufacturing practice (GMP) suites on the top floor and three clinical wards on the bottom floor. These were very early days that marked the start of our Translational Pharmaceutics platform. We continued to expand the range of scintigraphy applications we offered in response to changing customer requirements until, in 2008, when we approached the MHRA (UK’s Medicines and Healthcare products Regulatory Agency) with a new request. We asked if it might be possible to work at the same pace as we did in our scintigraphic imaging studies, but do so for conventional drug development, without the radiolabel. We explored the application of ICH Q8 Quality by Design (QbD) guidelines to introduce a compositional design space into the CMC section of our regulatory dossier. This officially created a methodology for applying the Translational Pharmaceutics platform, and we haven't looked back since. Today, we have expanded substantially. Our Nottingham site is a campus of five buildings. We have development and analytical labs, six GMP suites, six clinical wards with a total of 85 beds (where we conduct healthy volunteer phase 1 clinical studies), and many talented colleagues covering our spectrum of CRO and CDMO services. HIGHLIGHTS// officially created a methodology for applying the Translational Pharmaceutics platform/ development and analytical labs/ six GMP suites   How is Translational Pharmaceutics applied to drug development programs? We apply Translational Pharmaceutics across three core applications: first-in-human clinical studies, drug product optimization programs through rapid formulation development and clinical testing, and as a part of human ADME (absorption, distribution, metabolism, and excretion) programs. No matter how a client chooses to work with us to apply Translational Pharmaceutics, the benefits of using a single organization and project management team to integrate services lets our clients remain in control and one step ahead of the emerging data that impacts the success of their molecule. Over all these years, our flagship Translational Pharmaceutics platform for drug development has remained unchanged in the way it empowers our customers and offers them unparalleled flexibility. HIGHLIGHTS// three core applications/ benefits of using a single organization/ clients remain in control   What would you say are the key strengths of Quotient Sciences’ Nottingham site? How do you support customer programs? Nowhere else would a single project manager oversee such a broad spectrum of activities, let alone be expected to ensure seamless, timely progression across functions that in any other company (i.e. at other CDMOs or CROs) would be delivered through multiple operating areas or through the use of a combination of third-party vendors. The project managers do face challenges. But by working with the project team, they are able to anticipate, avoid, and mitigate any impact whenever necessary. We know that time is incredibly valuable for our customers. A project Gantt chart is our project management team’s guiding light. I believe our project management team is truly world-leading – they communicate well, show great compassion, and lead with integrity. I’m super proud of our high-performing, supportive, cross-functional teams that support our customers when they trust their molecules to us, and work collaboratively to deliver the best possible service. After 25 years at Quotient, I continue to really enjoy going to work. I am indebted to various colleagues for helping me continue to feel this way. HIGHLIGHTS// project management team is truly world-leading/ high-performing, supportive, cross-functional teams/ 25 years at Quotient  

    Impressions: 80

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility

    Radio Compass
    16 Dec 2024
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Every year, the US Food and Drug Administration (FDA) publishes the user fee amounts it will collect from manufacturers of pharmaceuticals, generic drugs, biosimilars and medical devices in the coming financial year. The fee for fiscal year 2025 under the Generic Drug User Fee Act (GDUFA) was published on July 31, 2024.The GDUFA, established in 2012, authorizes FDA to assess and collect fees from drug manufacturers to expedite the delivery of safe, high-quality, and affordable generic drugs to the American public.The FDA’s facility payments list under GDUFA reveals that as of November 14, 2024, 1,397 facilities had paid their registration fees for financial year 2025. Of these facilities, 707 or 50.6 percent are active pharmaceutical ingredients (API) facilities, 405 or 29 percent are finished dosage forms (FDF) facilities, 69 (4.9 percent) are facilities that produce both APIs and FDFs, and 216 (15.5 percent) are contract manufacturing services (CMO) sites.Teva Pharmaceuticals, with 29 facility registrations, led the list of companies, followed by Aurobindo Pharma, Sun Pharma, and Dr. Reddy's Laboratories. Fiscal year Facility Registrations 2016 1,425 2017 1,442 2018 1,269 2019 1,286 2020 1,300 2021 1,340 2022 1,385 2023 1,394 2024 1,447 2025 1,397  Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available)India continues to lead with 396 facilities, US and China follow India maintains its dominance in total facility registrations with the FDA, registering 396 facilities for FY2025. This includes 214 API facilities, 135 FDF facilities, 21 facilities engaged in both API and FDF activities, and 26 CMO facilities.The United States holds the second position with 328 facilities, while China strengthened its third position with 197 facilities.With 214 API facilities, India continues to have the largest share of API manufacturing sites, outmatching the combined total of China (128) and the US (83), which together account for 211 facilities. Among European manufacturers, Italy leads with 59 API manufacturing sites, followed by Spain (30) and Germany (25).The US has maintained its lead in FDF facilities with 143 sites, followed closely by India with 135 sites and China with 45 sites. Country API FDF Both CMO Total India 214 135 21 26 396 US 83 143 13 89 328 China 128 45 12 12 197 Italy 59 3 2 19 83 Germany 25 4 1 15 45 Spain 30 9 1 4 44 Canada 7 17   13 37 Taiwan 9 6 5 4 24 Switzerland 15 4   4 23 France 16     6 22 Japan 18   1   19 United Kingdom 12 1   2 15 Mexico 9 1   1 11 Ireland 5 5   1 11   Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) GDUFA III user fee rates increase across categories for FY25The GDUFA, which was reauthorized on September 30, 2022 (as GDUFA III), continues with provisions that will last until September 30, 2027. In July 2024, the FDA published updated user fee rates for FY2025.The facility fees have seen increases across all categories. API facility fees increased by 3 percent for domestic sites (to US$ 41,580) and 2 percent for foreign sites (to US$ 56,580). FDF facility fees rose by 5 percent for both domestic (to US$ 231,952) and foreign sites (to US$ 246,952). CMO facility fees increased by 5 percent for domestic sites (to US$ 55,668) and 4 percent for foreign sites (to US$ 70,668).Additionally, the fee for large-, medium- and small-sized drug applicants has increased by over 9 percent, compared to the 7 percent increase seen in 2023. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) China leads new facility registrations as FDA records 41 new units in FY25Out of the total 1,397 facilities registered for FY2025, 41 were new registrations (going by Facility FDA Establishment Identifier numbers). China led the way with 13 new facilities, followed closely by India with 11 new facilities, while the US secured the third position with eight new facilities.The new registrations included 15 API facilities, 13 CMO facilities, 12 FDF facilities, and one facility engaged in both API and FDF activities. Chinese companies dominated the new FDF registrations with six facilities: Chengdu Shuode Pharma, Chengdu Suncadia Medicine, Cipla (Jiangsu), GE Healthcare (Shanghai), Luoxin Aurovitas Pharma (Chengdu), and Zhejiang Xianju Pharma.India added two new FDF facilities through Eugia Steriles and Zydus Pharma. Malaysia registered two FDF facilities through Novugen Pharma and Novugen Oncology, while Turkey’s Insud Pharma subsidiary Exeltis and US’ RK Pharma registered one FDF facility each.The 13 new CMO facilities included, Acme Generics, Emcure, Esjay Pharma, Fordoz Pharma, Fourrts Laboratories, Laboratoires KABS, PharmaMax, Quality Packaging Specialists International, Ritsa Pharma, Shanghai Aucyun Pharma, Sichuan Huiyu Pharma, Taejoon Pharm, and Tubilux Pharma.In the API category, the 15 new registrations included Acharya Chemicals, Hainan Poly Pharma, CBL Patras, EUROAPI, Hybio Pharma, Medilux Laboratories, Metrochem API, Purolite, Chengdu Easton Biopharma, Sionc Pharma, Smithfield Bioscience, Xttrium Laboratories, Zhejiang Hengkang Pharma, Moehs Iberica and Shilpa Pharma. Armstrong Pharmaceuticals registered the sole facility for both APIs and FDFs.So far, 92 facilities have not renewed their registration. Among these was a facility owned by Sandoz subsidiary Eon Labs in Wilson, North Carolina (US), which is permanently closed. In fact, the geographical distribution of non-renewals shows that 30 facilities were from the US, while India and China accounted for 14 and nine non-renewals respectively. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) Our viewThe FY 2025 GDUFA facility registration data indicates a continued strong presence of Indian manufacturers in the US generic drug market, particularly in API production. However, China's leadership in new facility registrations, especially in FDF manufacturing, suggests that the global generic drug supply chain landscape may evolve considerably in the coming years. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 11457

    https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities

    #PharmaFlow by PHARMACOMPASS
    21 Nov 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Hikma`s Generics Ephedrine Sulfate Receives Approval in US
    Hikma`s Generics Ephedrine Sulfate Receives Approval in US

    11 Oct 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217721

    FDA
    11 Oct 2024
    Share Share
    Jazz, Hikma must face 'reverse payment' claims over narcolepsy drug
    Jazz, Hikma must face 'reverse payment' claims over narcolepsy drug

    27 Aug 2024

    // REUTERS

    https://www.reuters.com/legal/litigation/jazz-hikma-must-face-reverse-payment-claims-over-narcolepsy-drug-2024-08-27/

    REUTERS
    27 Aug 2024
    Share Share
    Hikma Participates In Naloxone Training With Congressman
    Hikma Participates In Naloxone Training With Congressman

    20 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/hikma-pharmaceuticals-participates-in-naloxone-training-event-with-us-congressman-buddy-carter-ahead-of-national-fentanyl-awareness-and-prevention-day-302226540.html

    PR NEWSWIRE
    20 Aug 2024
    Share Share
    KLOXXADO Naloxone Nasal Spray Shelf-Life Extended To 36 Months
    KLOXXADO Naloxone Nasal Spray Shelf-Life Extended To 36 Months

    15 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kloxxado-8mg-naloxone-nasal-spray-shelf-life-extended-from-24-months-to-36-months-302223864.html

    PR NEWSWIRE
    15 Aug 2024
    Share Share
    FDA Issues Form 483 to Hikma Injectables USA
    FDA Issues Form 483 to Hikma Injectables USA

    26 Jul 2024

    // FDA

    https://www.fda.gov/media/180065/download

    FDA
    26 Jul 2024
    Share Share
    Hikma Extends Pain Drug Recall Due To Potential Sedative Presence
    Hikma Extends Pain Drug Recall Due To Potential Sedative Presence

    23 Jul 2024

    // FIERCE PHARMA

    https://www.fiercepharma.com/manufacturing/sedative-potentially-inside-packaging-one-lot-pain-med-injections-prompts-extended

    FIERCE PHARMA
    23 Jul 2024
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact HIKMA PHARMACEUTICAL CO. LTD. and get a quotation

    HIKMA PHARMACEUTICAL CO. LTD. is a supplier offers 30 products (APIs, Excipients or Intermediates).

    Find a price of Ondansetron Hydrochloride bulk with DMF offered by HIKMA PHARMACEUTICAL CO. LTD.

    Find a price of Betamethasone Acetate bulk with DMF offered by HIKMA PHARMACEUTICAL CO. LTD.

    Find a price of Dasatinib bulk with DMF offered by HIKMA PHARMACEUTICAL CO. LTD.

    Find a price of Enalaprilat bulk with DMF offered by HIKMA PHARMACEUTICAL CO. LTD.

    Find a price of Erlotinib Hydrochloride bulk with DMF offered by HIKMA PHARMACEUTICAL CO. LTD.

    Find a price of Glycopyrronium Bromide bulk with DMF offered by HIKMA PHARMACEUTICAL CO. LTD.

    Find a price of Granisetron Hydrochloride bulk with DMF offered by HIKMA PHARMACEUTICAL CO. LTD.

    Find a price of Hydrocortisone bulk with DMF offered by HIKMA PHARMACEUTICAL CO. LTD.

    Find a price of Methylprednisolone Acetate bulk with DMF offered by HIKMA PHARMACEUTICAL CO. LTD.

    Find a price of Milrinone bulk with DMF offered by HIKMA PHARMACEUTICAL CO. LTD.

    Find a price of Nicardipine Hydrochloride bulk with DMF offered by HIKMA PHARMACEUTICAL CO. LTD.

    Find a price of Nilotinib bulk with DMF offered by HIKMA PHARMACEUTICAL CO. LTD.

    Find a price of Oxandrolone bulk with DMF offered by HIKMA PHARMACEUTICAL CO. LTD.

    Find a price of Prednisone bulk with DMF offered by HIKMA PHARMACEUTICAL CO. LTD.

    Find a price of Solriamfetol Hydrochloride bulk with DMF offered by HIKMA PHARMACEUTICAL CO. LTD.

    Find a price of Sunitinib bulk with DMF offered by HIKMA PHARMACEUTICAL CO. LTD.

    Find a price of Umeclidinium Bromide bulk with DMF offered by HIKMA PHARMACEUTICAL CO. LTD.

    Find a price of Zoledronic Acid bulk with DMF offered by HIKMA PHARMACEUTICAL CO. LTD.

    Find a price of HIK-078 bulk with DMF offered by HIKMA PHARMACEUTICAL CO. LTD.

    Find a price of HIK-079 bulk with DMF offered by HIKMA PHARMACEUTICAL CO. LTD.

    Find a price of Cefadroxil bulk offered by HIKMA PHARMACEUTICAL CO. LTD.

    Find a price of Cortisone bulk offered by HIKMA PHARMACEUTICAL CO. LTD.

    Find a price of FACILITIES, PERSONNEL AND GENERAL OPERATING PROCEDURES IN AMMAN JORDON bulk offered by HIKMA PHARMACEUTICAL CO. LTD.

    Find a price of MANUFACTURING SITE, FACILITIES, OPERATING PROCEDURES AND PERSONNEL IN AMMAN, JORDAN bulk offered by HIKMA PHARMACEUTICAL CO. LTD.

    Find a price of Benztropine bulk offered by HIKMA PHARMACEUTICAL CO. LTD.

    Find a price of Fluticasone Propionate bulk offered by HIKMA PHARMACEUTICAL CO. LTD.

    Find a price of Ibrutinib bulk offered by HIKMA PHARMACEUTICAL CO. LTD.

    Find a price of Prifinium Bromide bulk offered by HIKMA PHARMACEUTICAL CO. LTD.

    Find a price of Ruxolitinib Phosphate bulk offered by HIKMA PHARMACEUTICAL CO. LTD.

    Find a price of Thiotepa bulk offered by HIKMA PHARMACEUTICAL CO. LTD.

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search